Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.3.1369

Pre-treatment Metabolic Tumor Volume and Total Lesion Glycolysis are Useful Prognostic Factors for Esophageal Squamous Cell Cancer Patients  

Li, Yi-Min (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University)
Lin, Qin (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University)
Zhao, Long (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University)
Wang, Li-Chen (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University)
Sun, Long (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University)
Dai, Ming-Ming (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University)
Luo, Zuo-Ming (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University)
Zheng, Hua (Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University)
Wu, Hua (Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.3, 2014 , pp. 1369-1373 More about this Journal
Abstract
Objectives: To study application of the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) with $^{18}F$-FDG PET/CT for predicting prognosis of esophageal squamous cell cancer (ESC) patients. Methods: Eighty-six patients with ESC staged from I to IV were prospectively enrolled. Cisplatin-based chemoradiotherapy (CCRT) or palliative chemoradiotherapy were the main treatment methods and none received surgery. $^{18}F$-FDG PET/CT scans were performed before the treatment. SUVmax, MTV, and TLG were measured for the primary esophageal lesion and regional lymph nodes. Receiver operating characteristic curves (ROCs) were generated to calculate the P value of the predictive ability and the optimal threshold. Results: MTV and TLG proved to be good indexes in the prediction of outcome for the ESC patients. An MTV value of 15.6 ml and a TLG value of 183.5 were optimal threshold to predict the overall survival (OS). The areas under the curve (AUC) for MTV and TLG were 0.74 and 0.70, respectively. Kaplan-Meier analysis showed an MTV less than 15.6 ml and a TLG less than 183.5 to indicate good media survival time (p value <0.05). In the stage III-IV patient group, MTV could better predict the OS (P < 0.001), with a sensitivity and specificity of 0.80 and 0.67, respectively. Conclusions: Pre-treatment MTV and TLG are useful prognostic factors in nonsurgical ESC.
Keywords
$^{18}F$ deoxyglucose; positron emission tomography; esophageal SCC; chemoradiotherapy; survival analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Westerterp M, Sloof GW, Hoekstra OS, et al (2008). 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol, 134, 227-36.   DOI   ScienceOn
2 Roedl JB, Colen RR, Holalkere NS, et al (2008). Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol, 89, 278-86.   DOI   ScienceOn
3 Liao S, Penney BC, Zhang H, Suzuki K, Pu Y (2012). Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer. Nucl Med Mol Imaging, 19, 69-77.
4 Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M (1999). Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med, 40, 1771-7.
5 Zhu WQ, Sun XR (2011). The prognostic value of metabolic tumor volume in FDG PET/CT evaluation of post-operative survival in patients with esophageal squamous cell cancer[in Chinese]. Chin J Nucl Med, 31, 378-81.
6 Hong D, Lunagomez S, Kim EE, et al (2005). Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer, 104, 1620-6.   DOI   ScienceOn
7 Greene FL (2002). The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg, 87, 13-5.
8 Hellwig D, Graeter TP, Ukena D, et al (2007). $^{18}F$-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med, 48, 1761-6.   DOI
9 Herskovic A, Martz K, al-Sarraf M, et al (1992). Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 326, 1593-8.   DOI   ScienceOn
10 Hyun SH, Choi JY, Shim YM, et al (2010). Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol, 17, 115-22.   DOI   ScienceOn
11 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
12 Klaeser B, Nitzsche E, Schuller JC, et al (2009). Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie, 32, 724-30.   DOI   ScienceOn
13 Omloo JM, Sloof GW, Boellaard R, et al (2008). Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy, 40, 464-71.   DOI   ScienceOn
14 Rizk N, Downey RJ, Akhurst T, et al (2006). Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg, 81, 1076-81.   DOI   ScienceOn
15 Bradley J, Thorstad WL, Mutic S, et al (2004). Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 59, 78-86.   DOI   ScienceOn
16 Cooper JS, Guo MD, Herskovic A, et al (1999). Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 281, 1623-7.
17 Shen K, Huang XE, Lu YY, et al (2012). Phase II study of docetaxel (Aisu$^{(R)}$) combined with three- dimensional conformal external beam radiotherapy in treating patients with inoperable esophageal cancer. Asian Pac J Cancer Prev, 13, 6523-6.   과학기술학회마을   DOI   ScienceOn
18 Ma JB, Chen EC, Song YP, et al (2013). Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (PET)-based parameters in neoadjuvant chemoradiation treatment of esophageal carcinoma. Asian Pac J Cancer Prev, 14, 2477-81.   과학기술학회마을   DOI   ScienceOn